Bharat Biotech to supply GSK’s malaria vaccine to GAVI in ’26

• Vaccine Price Reduction Announcement

• Bharat Biotech International Ltd. (BBIL) and GSK pledged to reduce the price of the RTS,S malaria vaccine to below USD 5 by 2028.

• Higher production capacity

• Cost-effective manufacturing

• Low-margin pricing strategy

• Linked to the Gavi 6.0 replenishment period (2026–2030).

• RTS,S is the first malaria vaccine recommended by the WHO (in 2021).

• GSK developed the vaccine in partnership with PATH and others.

• GSK began technology transfer to Bharat Biotech in 2021.

• Full transition of manufacturing to BBIL expected by 2028.

• Bharat Biotech has invested over USD 200 million in vaccine production infrastructure.

• With Gavi’s support, 12 African countries are set to integrate RTS, S into routine immunisation by end of 2025.

WHO’s Malaria Vaccine Implementation Programme (MVIP) data (2019–2023) showed:

• 13% reduction in all-cause mortality

• 22% reduction in severe malaria hospitalisations among vaccinated children

• 75% prevention of malaria episodes when combined with seasonal chemoprevention

• RTS, S is used alongside WHO-recommended tools: chemoprevention, treatments, indoor spraying (IRS), and bed nets.

• GSK is also developing a second-generation malaria vaccine, targeting a different parasite stage.

• Stakeholders involved: GSK, Bharat Biotech, Gavi, WHO, PATH, MedAccess, and African implementing countries.

• Aimed at sustained affordability, access, and equity in vaccine delivery.